Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

被引：6

作者：

Huber, Henriette ^{[1
,2
]}

Tausch, Eugen ^{[2
]}

Schneider, Christof ^{[2
]}

Edenhofer, Simone ^{[3
]}

Von Tresckow, Julia ^{[4
,5
,6
,7
]}

Robrecht, Sandra ^{[5
,6
,8
]}

Giza, Adam ^{[5
,6
,8
]}

Zhang, Can ^{[5
,6
,9
,10
]}

Furstenau, Moritz ^{[5
,6
,9
,10
]}

Dreger, Peter ^{[11
]}

Ritgen, Matthias ^{[12
]}

Illmer, Thomas ^{[13
]}

Illert, Anna Lena ^{[14
]}

Duerig, Jan ^{[15
]}

Boettcher, Sebastian ^{[16
]}

Niemann, Carsten Utoft ^{[17
]}

Kneba, Michael ^{[18
]}

Fink, Anna-Maria ^{[5
,6
,9
,10
]}

Fischer, Kirsten ^{[9
,10
,19
,20
,21
]}

Doehner, Hartmut ^{[2
]}

Hallek, Michael ^{[22
]}

Eichhorst, Barbara ^{[23
,24
]}

Stilgenbauer, Stephan ^{[2
]}

机构：

[1] Stadt Klinikum Karlsruhe, Dept Internal Med 3, Karlsruhe, Germany

[2] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[3] Ulm Univ Hosp, Ulm, Germany

[4] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Clin Hematol & Stem Cell Transplantat, Essen, Germany

[5] Dept Internal Med 1, Cologne, Germany

[6] Ctr Integrated Oncol Aachen, Cologne, Germany

[7] Univ Cologne, Cologne, Germany

[8] Univ Hosp Cologne, German CLL Study Grp, Cologne, Germany

[9] Univ Cologne, Fac Med, German CLL Study Grp, Cologne, Germany

[10] Univ Cologne, Univ Hosp Cologne, Cologne, Germany

[11] Heidelberg Univ, Dept Med 5, Heidelberg, Germany

[12] Univ Schleswig Holstein, Dept Internal Med 2, Kiel, Germany

[13] BAG Onkol Schwerpunktpraxis, Dresden, Germany

[14] Univ Med Ctr Freiburg, Dept Internal Med 1, Freiburg, Germany

[15] Essen Univ Hosp, Dept Hematol, Essen, Germany

[16] Univ Med Sch, Clin 3, Special Hematol Lab, Rostock, Germany

[17] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark

[18] Univ Schleswig Holstein, Campus Kiel, Kiel, Germany

[19] Fac Med, Cologne, Germany

[20] Univ Hosp Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen, Cologne, Germany

[21] German CLL Study Grp, Dept Internal Med 1, Cologne, Germany

[22] Univ Hosp Cologne, Dept Internal Med 1, Leukapheresis & Stem Cell Transplant Unit, Cologne, Germany

[23] Univ Hosp, Dept Internal Med 1, Cologne, Germany

[24] Univ Hosp, Ctr Integrated Oncol Cologne Bonn, German CLL Study Grp, Cologne, Germany

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163245

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 22 条

[1] Final Analysis of the Prospective Multicenter CLL2- GIVe Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
Huber, H.
Edenhofer, S.
von, Tresckow J.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
[2] Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
Huber, Henriette
Tausch, Eugen
Schneider, Christof
Edenhofer, Simone
von Tresckow, Julia
Robrecht, Sandra
Giza, Adam
Zhang, Can
Fuerstenau, Moritz
Dreger, Peter
Ritgen, Matthias
Illmer, Thomas
Illert, Anna Lena
Duerig, Jan
Boettcher, Sebastian
Niemann, Carsten U.
Kneba, Michael
Al-Sawaf, Othman
Kreuzer, Karl -Anton
Fink, Anna -Maria
Fischer, Kirsten
Doehner, Hartmut
Hallek, Michael
Eichhorst, Barbara
Stilgenbauer, Stephan
BLOOD, 2023, 142 (11) : 961 - 972
[3] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients With CLL With Mutated IGHV and Without TP53 Aberration
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 6 - 8
[4] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
Jain, Nitin
Thompson, Philip
Burger, Jan
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Takahashi, Koichi
Garg, Naveen
Wang, Xuemei
Gandhi, Varsha
Plunkett, William
Kanagal-Shamanna, Rashmi
Patel, Keyur
Lopez, Wanda
Kantarjian, Hagop
O'Brien, Susan
Keating, Michael
Wierda, William
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S13 - S14
[5] Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations
Sivina, Mariela
Kim, Ekaterina
Wierda, William G.
Ferrajoli, Alessandra
Jain, Nitin
Thompson, Philip
Kantarjian, Hagop
Keating, Michael
Burger, Jan A.
BLOOD, 2021, 138 (24) : 2589 - 2592
[6] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17p)
Jain, Nitin
Thompson, Philip
Burger, Jan A.
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Gandhi, Varsha
Plunkett, William
Lopez, Wanda
Kantarjian, Hagop
O'Brien, Susan
Keating, Michael
Wierda, William
LEUKEMIA & LYMPHOMA, 2017, 58 : 158 - 159
[7] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).
Jain, Nitin
Thompson, Philip A.
Burger, Jan Andreas
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Gandhi, Varsha
Plunkett, William
Lopez, Wanda
Kantarjian, Hagop M.
O'Brien, Susan Mary
Keating, Michael J.
Wierda, William G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8] IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
Jain, N.
Thompson, P.
Burger, J.
Borthakur, G.
Bose, P.
Estrov, Z.
Ferrajoli, A.
Gandhi, V.
Plunkett, W.
Lopez, W.
Kantarjian, H.
O'Brien, S.
Keating, M.
Wierda, W.
HAEMATOLOGICA, 2017, 102 : 171 - 171
[9] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Jain, Nitin
Thompson, Philip A.
Burger, Jan A.
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Takahashi, Koichi
Garg, Naveen
Wang, Xuemei
Gandhi, Varsha
Plunkett, William
Kanagal-Shamanna, Rashmi
Patel, Keyur
Lopez, Wanda
Kantarjian, Hagop M.
O'Brien, Susan M.
Keating, Michael J.
Wierda, William G.
BLOOD, 2017, 130
[10] Copy Number Aberrations are Significantly Increased in High-Risk, Untreated CLL Patients with Chromosome 17p Deletion and TP53 Mutation
Stone, A.
Carter, W.
Frederick, L.
Zent, C. S.
Viswanatha, D. S.
Schichman, S. A.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 870 - 870

← 1 2 3 →